Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

Inclusion Criteria: * PRIOR TO STEP 1 REGISTRATION * Tumor tissue must be available for submission for central pathology review * Grade II and III gliomas IDH mutant gliomas including; diffuse astrocytoma, anaplastic astrocytoma, oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytoma, anaplastic oligoastrocytoma * Documentation from the enrolling site confirming the presence of IDH mutation and 1p/19q status; the provided information must document assays performed in clinical laboratory improvement amendments (CLIA)-approved laboratories and be uploaded prior to Step 2 registration * Age \>= 18 * The trial is open to both genders * Only English or French speaking patients are eligible to participate as the cognitive assessments are only available in these languages * The patient or a legally authorized representative must provide study-specific informed consent prior to study entry * History and physical exam, and Karnofsky performance status of \>= 70 within 30 days prior to registration * Absolute neutrophil count (ANC) \>= 1,500 cells/mm\^3 (within 60 days prior to registration) * Platelets \>= 100,000 cells/mm\^3 (within 60 days prior to registration) * Hemoglobin \>= 10.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin \[Hgb\] \>= 10.0 g/dl is acceptable) (within 60 days prior to registration) * Bilirubin =\< 1.5 upper limit of normal (ULN) (within 60 days prior to registration) * Alanine aminotransferase (ALT) and aspartate ami…